Literature DB >> 33731364

Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study.

Carly Sy Lam1,2, Wing Chun Tang3, Paul H Lee4, Han Yu Zhang3, Hua Qi5, Keigo Hasegawa5, Chi Ho To3,2.   

Abstract

AIMS: To determine myopia progression in children who continued to wear the defocus incorporated multiple segments (DIMS) lenses or switched from single vision (SV) to DIMS lenses for a 1-year period following a 2-year myopia control trial.
METHODS: 128 children participated in this study. The children who had worn DIMS lenses continued to wear DIMS lenses (DIMS group), and children who had worn SV lenses switched to wear DIMS lenses (Control-to-DIMS group). Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at 6-month interval. Historical controls were age matched to the DIMS group at 24 months and used for comparing the third-year changes.
RESULTS: Over 3 years, SER and AL changes in the DIMS group (n=65) were -0.52±0.69D and 0.31±0.26 mm; these changes were not statistically significant over time (repeated measures analysis of variance, p>0.05).SER (-0.04±0. 38D) and AL (0.08±0.12 mm) changes in the Control-to-DIMS group (n=55) in the third year were less compared with the first (mean difference=0.45 ± 0.30D, 0.21±0.11 mm, p<0.001) and second (0.34±0.30D, 0.12±0.10 mm, p<0.001) years.Changes in SER and AL in both groups over that period were significantly less than in the historical control group (DIMS vs historical control: mean difference=-0.18±0.42D, p=0.012; 0.08±0.15 mm, p=0.001; Control-to-DIMS versus historical control: adjusted mean differences=-0.30±0.42D, p<0.001; 0.12±0.16 mm, p<0.001).
CONCLUSIONS: Myopia control effect was sustained in the third year in children who had used the DIMS spectacles in the previous 2 years and was also shown in the children switching from SV to DIMS lenses. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  child health (paediatrics); clinical trial

Mesh:

Year:  2021        PMID: 33731364      PMCID: PMC9340033          DOI: 10.1136/bjophthalmol-2020-317664

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   5.908


Introduction

The prevalence of myopia is growing alarmingly worldwide, especially in East Asian populations.1–3 High myopia is associated with an increased risk of sight-threatening eye disease4–6 creating a long-term burden on economies and public healthcare.7 8 There is no doubt that myopia is a significant public health issue and a global concern.8 Effective interventions for myopia management and reduction would alleviate this problem. Currently, a variety of modalities are used for myopia control in children.9–11 High-dose (1%) atropine eye-drops seem the most effective in myopia control, but the associated side effects, such as photophobia and blurred near vision, hinder its wide clinical application.12 In recent years, some studies have reported that low-dose (0.01%) atropine treatment has yielded positive results with minimal side effects and low myopic rebound.13–15 Optical treatments, including orthokeratology,16–18 executive top bifocal spectacles19 and multifocal soft contact lenses incorporating myopic defocus20–24 have also shown promising results in slowing myopia progression. However, each method has limitations.11 The defocus incorporated multiple segments (DIMS) spectacle lens is designed to control myopia in children, based on the principle of myopic defocus and simultaneous vision. It is a dual-focus spectacle lens consisting of a central optical zone for correcting distance refractive error, and a batch of tiny circular segments with a relative positive power of 3.50D equally distributed throughout the mid-peripheral area in a honeycomb pattern.25 Thus, the DIMS lens imposes myopic defocus while providing clear vision for the wearer simultaneously at all viewing distances. A 2-year double-masked randomised controlled trial (RCT) (ClinicalTrials.gov: NCT02206217) showed that DIMS lens wear slowed childhood adjusted myopia progression significantly by 52% and axial elongation by 62% compared with regular single vision (SV) spectacle lenses wear over 2 years.25 Our aims here are to determine (1) if myopia retardation (as measured by changes in spherical equivalent refraction (SER) and AL) continues in the third year of DIMS wear and (2) if myopia retardation is exhibited in the first year of DIMS wear by the original SV control group; both groups will be compared with a new historical control group.

Materials and methods

Study participants

Ethnic Chinese children who had completed the 2-year RCT25 (NCT02206217, between August 2014 and July 2017) were invited to participate in this third-year follow-up study. Written assent and informed consent were obtained from the children and their parents respectively before participation. Children who had worn DIMS lenses in the RCT continued to wear DIMS lenses in the third year (DIMS group). The children in the original control group were offered the DIMS treatment and this gave us the opportunity to evaluate if the DIMS lenses could provide myopia control in the Control-to-DIMS group similar to that observed in the original DIMS group.

Study procedures and data collection

The primary and secondary outcomes were the changes in SER and axial length (AL). The procedures of data measurement followed those in the trial of DIMS lenses.25 SER and AL were measured at 6-month intervals. SER was measured by cycloplegic autorefraction using an open-field autorefractor (Shin-Nippon NVision-K5001, Ajinomoto Trading Inc.). AL was measured by partial coherence interferometry using an IOL Master (Carl Zeiss Meditec). Cycloplegia was induced by instillation of one drop of alcaine 0.5%, followed by one to two drops of cyclopentolate HCL 1%. The measurements were taken 30 min after the instillation of eye drops, and cycloplegia was considered achieved when the amplitude of accommodation was less than 2.00D as measured using an RAF rule. An average of five autorefractions and AL measurements for each eye was used for data analysis.

The historical control group

Since the children originally in the control group switched to wear DIMS lenses in the third year, they could not be used as the ‘control’ to assess effectiveness on myopia control. Therefore, we obtained a historical control group by reviewing clinical records from the Optometry Clinic, PolyU for 2017–2019. The criteria for selection were based on the inclusion and exclusion criteria in the original RCT. Subjects were healthy myopic ethnic Chinese children who attended eye examinations in the clinic with at least 12-month follow-up data. They had not received any myopia interventions and were matched for age (between 10 and 15 years) and SER ranges (−1.00 to −5.50D) with the DIMS subjects at the end of the 2-year RCT. Annual myopia progression and AL changes in this group of children were calculated and compared with the third-year changes in the DIMS and Control-to-DIMS groups.

Statistical analysis

All statistical analyses were performed using SPSS V.20.0. Baseline characteristics and the changes in SER and AL are presented as mean±SD. The right eye data only were used for analysis as there was no statistically significant difference between the left and the right eye data. Following Kolmogorov-Smirnov tests for distribution, unpaired t-tests, Mann-Whitney U tests or repeated measures analysis of variance (ANOVA) tests were used as appropriate. Pearson’s correlation coefficient analyses were used to determine relationships between continuous variables and χ2 tests for categorical data. For both the DIMS group and Control-to-DIMS group, myopia progression and changes in AL in years 1, 2 and 3 were calculated and compared by repeated measures ANOVA and post hoc pairwise comparisons using Bonferroni corrections were performed for determining where the differences laid. Myopia progression and change in AL were calculated for the historical control group, for which we had one (12 months) set of data, and were compared with the third-year changes of two experimental groups by multiple linear regression approach with adjusting confounding covariates, such as age, sex, SER and AL.

Results

Subject profile and baseline data

Figure 1 shows the number of subjects recruited and those lost to follow-up over 3 years. One hundred and sixty Chinese children completed the 2-year RCT and 128 of these agreed to participate in the third-year study. We compared the data between the subjects who joined and those who declined to join the third-year study for both the DIMS and Control-to-DIMS groups. No significant differences were found in terms of their age, gender, baseline myopia or AL, myopia progression or axial elongation in the previous 2-year trial (p>0.05) (online supplemental eTable 1).
Figure 1

Subject numbers over 3 years. DIMS, defocus incorporated multiple segments; SV, single vision.

Subject numbers over 3 years. DIMS, defocus incorporated multiple segments; SV, single vision. At the end of the third year, 120 children (DIMS, n=65; Control-to-DIMS, n=55) completed the data collection. The mean age at enrolment (mean±SD) was 10.15±1.52 years and 10.24±1.42 years in the DIMS and the Control-to-DIMS groups, respectively. The baseline SER of the DIMS group and the Control-to-DIMS were −2.98±0.96D and −2.73±0.99D, respectively. The baseline AL of the DIMS and the Control-to-DIMS were 24.68±0.82 mm and 24.57±0.88 mm. There were no statistically significant differences between the two groups with respect to age at enrolment, gender proportion, baseline myopia or baseline AL (p>0.05).

Changes in SER and AL

Figure 2A and table 1 present the mean and cumulative changes in mean SER and AL from baseline to 36 months in both groups. Figure 2B shows the trend in changes in SER and AL changes in the third year.
Figure 2

(A) Changes in spherical equivalent refraction (SER) and axial length (AL) from baseline to 36 months. The red dotted line represents the period (24–36 months) during which the previous single vision control group wore defocus incorporated multiple segments (DIMS) lenses. (B) The third-year changes in SER and AL in the DIMS and Control-to-DIMS groups. The green line shows the 12-month changes in SER and AL in the historical control group.

Table 1

Mean and cumulative changes in the cycloplegic SER and AL from baseline to 36 months in the DIMS group and Control-to-DIMS group

Time (months)Mean±SD
DIMS(n=65)Control-to-DIMS(n=55)DIMS(n=65)Control-to-DIMS(n=55)
SER (D)Changes in SER (D)
0−2.98±0.96−2.73±0.99
6−3.10±0.97−3.07±1.02−0.12±0.30−0.34±0.33
12−3.16±0.97−3.22±1.08−0.18±0.37−0.49±0.40
18−3.23±0.96−3.41±1.09−0.25±0.50−0.68±0.52
24−3.32±1.00−3.61±1.15−0.34±0.52−0.87±0.59
30−3.39±1.01−3.73±1.23−0.41±0.58−1.00±0.67
36−3.50±1.08−3.65±1.34−0.52±0.69−0.92±0.81
Time (months) AL (mm) Changes in AL (mm)
024.68±0.8224.57±0.88
624.72±0.8124.75±0.890.04±0.100.18±0.09
1224.78±0.8124.86±0.910.10±0.140.29±0.14
1824.81±0.8124.97±0.930.13±0.180.40±0.18
2424.88±0.8025.06±0.960.20±0.210.49±0.24
3024.93±0.7925.12±0.990.25±0.240.55±0.27
3624.99±0.8025.14±1.010.31±0.260.57±0.33

The grey blocks indicate the period of wearing DIMS lenses in the Control-to-DIMS group.

AL, axial length; Control-to-DIMS, subjects wore single vision spectacle lens during the 2-year randomised controlled trial and switched to wear DIMS lens; D, dioptres; DIMS, defocus incorporated multiple segments; SER, spherical equivalent refraction.

(A) Changes in spherical equivalent refraction (SER) and axial length (AL) from baseline to 36 months. The red dotted line represents the period (24–36 months) during which the previous single vision control group wore defocus incorporated multiple segments (DIMS) lenses. (B) The third-year changes in SER and AL in the DIMS and Control-to-DIMS groups. The green line shows the 12-month changes in SER and AL in the historical control group. Mean and cumulative changes in the cycloplegic SER and AL from baseline to 36 months in the DIMS group and Control-to-DIMS group The grey blocks indicate the period of wearing DIMS lenses in the Control-to-DIMS group. AL, axial length; Control-to-DIMS, subjects wore single vision spectacle lens during the 2-year randomised controlled trial and switched to wear DIMS lens; D, dioptres; DIMS, defocus incorporated multiple segments; SER, spherical equivalent refraction.

The DIMS group

The mean changes in SER and AL in the DIMS group (n=65) were −0.52± 0.69D and 0.31± 0.26 mm over 3 years (table 1). The myopia progression and axial elongation did not change significantly over time (repeated measures ANOVA, p>0.05). The mean annual changes in SER and AL in the DIMS group were −0.18± 0.25D and 0.10± 0.09 mm over 3 years.

The Control-to-DIMS group

In the Control-to-DIMS group (n=55), myopia progression and axial elongation were significantly different between the 3 years (repeated measures ANOVA, p<0.001). Post hoc analyses indicated that their myopia progression and axial elongation in the third year were significantly decreased compared with the first (mean difference=0.45±0.30D, 0.21±0.11 mm, p<0.001) and second years (mean difference=0.34±0.30D, 0.12± 0.10 mm, p<0.001) (figure 2A).

DIMS compared with Control-to-DIMS in SER and AL changes

There were no statistically significant differences in myopia progression and axial elongation in the third year between the Control-to-DIMS group and the DIMS group ((p>0.05) (figure 2B). The myopia of 80% of the subjects in the DIMS group progressed by less than 0.5D in the third year, compared with 87% in the Control-to-DIMS group. Only 5% and 2% in the DIMS and Control-to-DIMS groups, respectively, had myopia progression more than 1D. 52% and 58% in the DIMS and Control-to-DIMS groups had axial elongation less than 0.1 mm (figure 3).
Figure 3

Distributions of myopia progression and axial elongation in the third year. DIMS, defocus incorporated multiple segments.

Distributions of myopia progression and axial elongation in the third year. DIMS, defocus incorporated multiple segments.

DIMS compared with the historical control group in SER and AL changes

The historical control group (n=76, 39 males and 37 females) had a mean age of 12.19±0.71 years, baseline SER and AL were −2.93± 1.33D and 24.77± 0.91 mm. Baseline characteristics of the historical control group did not differ statistically significantly from those of DIMS groups at 24 months (p>0.05) (online supplemental eTable 2). The 12-month changes in SER and AL in the historical control group were −0.35± 0.40D and 0.18± 0.14 mm. The myopia progression in the DIMS group in the third year was significantly less than in the historical control group (mean difference=−0.18±0.42D, p=0.012). Axial elongation in the DIMS group was also less than in the historical control group (mean differences=0.08±0.15 mm, p=0.001).

Control-to-DIMS compared with the historical control group in SER and AL changes

There were no significant differences between the baseline data of the historical control group and the 24-month data in the Control-to-DIMS group, in terms of age, sex or AL, however, SER was significantly less in the historical control group than in the Control-to-DIMS group (p=0.003), the historical control group having been matched to the DIMS group (online supplemental eTable 3). The children in the Control-to-DIMS group switched to wear DIMS spectacles in the third year. After adjusting for baseline SER, their myopia progression over that period was significantly slower than in the historical control group (mean differences=−0.30±0.42D, p<0.001). A similar result was found in the AL changes after controlling the cofounding factor (mean differences=0.12±0.16 mm, p<0.001).

Discussion

Myopia progression and axial elongation were less in the subjects wearing DIMS lenses throughout the 3 years, first compared with the initial control group (which subsequently became the Control-to-DIMS group), and then in the last 12 months compared with the historical control group. In the DIMS group, myopia progression and axial elongation in the third year were similar to those in the first and second years (figure 2A—blue line).

Overall myopia progression

The mean changes in SER and AL in the DIMS treatment group over the 3-year period were −0.52±0.69D and 0.31±0.26 mm. These findings are comparable with the corresponding findings in the 3-year trial with dual power contact lenses by Chamberlain et al 24 (-0.51±0.64D and 0.30±0.27 mm) and the 3-year trial with multifocal soft contact lenses by Walline et al 26 (-0.60D, range −0.72 to −0.47D and 0.39 mm, range 0.32–0.46 mm). Our progression findings were nearly 50% less than reported by Cheng et al 19 in a 3-year trial with bifocal and prismatic bifocal spectacle lenses which included subjects with fast myopia progression (−1.25±0.10D for the bifocal treatment group, and −1.01±0.13D for the prismatic bifocal treatment group).

Myopia retardation in DIMS and Control-to-DIMS groups

The mean changes in SER and AL in the DIMS group were −0.18±0.37D and 0.10±0.14 mm in the first year and, −0.17±0.31D and 0.10±0.11 mm in the second year. In the first 2 years, myopia progression and axial elongation in the DIMS group were retarded by 0.53D and 0.29 mm compared with the original control group. The mean annual SER and AL changes in the historical control group aged from 10 to 15 years were −0.35D and 0.18 mm; when compared with the DIMS group’s third year changes in SER and AL, myopia progression and axial elongation in the DIMS group were retarded by 0.18D and 0.08 mm, respectively (figure 2B). The overall 3 years control effect in the DIMS group would be myopia retardation by 0.71D and AL decrease by 0.37 mm. Cheng et al 19 reported that in a selected group of fast progressing myopic children wearing executive top bifocal spectacles with and without prisms, lowered myopia progression by 0.81D and 1.05D compared with SV spectacle lenses wearing children. Chamberlain et al 24 showed that a dual power soft contact lens significantly slowed myopia progression by 0.73D in children of various ethnicity aged 8–12 years. Walline et al reported in their BLINK clinical trial that children wearing high add power (+2.50D) multifocal contact lenses had 0.46D less myopia progression over 3 years.26 The reduction of myopia progression by the wearing of DIMS lenses is comparable to the findings from these studies using bifocals, dual focus and multifocal soft contact lenses. The subjects in the Control-to-DIMS group showed significant reductions in myopia progression and axial elongation after switching from SV to DIMS lenses wear (figure 2B). Their changes in SER and AL in the third year were comparable to the first-year changes in the DIMS group, even though these subjects were 2 years older. In comparison to the historical control group, their myopia progression and axial elongation in the third year, after adjustment were reduced by 86% and 61%, respectively. In the third year, more than 80% of the Control-to-DIMS children had myopia progression less than 0.5D, and approximately 70% showed progression less than 0.25D. All these findings suggested that the myopia control effect was achieved even though the subjects started to wear DIMS lenses at an older age.

Limitations

A limitation of this study was that the cohort used in the analyses comprised the DIMS plus the Control-to-DIMS groups of children so that the study was no longer randomised. This follow-up study, however, did benefit from the comparison of the third-year myopia progression findings in the DIMS group with the Control-to-DIMS group. While there were no statistically significant differences between the DIMS group and the historical control group at the start of the third year, there was a statistically significant difference in SER between the historical control group and the Control-to-DIMS group at baseline. This was because the historical control group was matched with the DIMS group at 24 months for age and SER and as the Control-to-DIMS group had no treatment in the first 2 years it could be expected to have more myopic SER. Although adjustment was made in the comparison, this approach does not eliminate the effect that can result from known or unknown factors, such as different examiners, the number of myopic parents and time spent on near and outdoor activities, and potentially could lead to selection bias for estimating the treatment efficacy of the DIMS lens.

Conclusions

The DIMS spectacle lens slowed myopia progression and axial elongation in children throughout the 3 years of study and the myopia control effect was also demonstrated in the Control-to-DIMS group. These findings provided further evidence that DIMS lenses slowed myopia progression and axial elongation in children. The optimal age at which treatment should commence is still to be determined and further monitoring is required to ascertain the treatment effect over a longer period. We also plan to follow up on those children who discontinued wearing the DIMS lenses to determine if rebound occurs.
  25 in total

1.  Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.

Authors:  Jason C Yam; Yuning Jiang; Shu Min Tang; Antony K P Law; Joyce J Chan; Emily Wong; Simon T Ko; Alvin L Young; Clement C Tham; Li Jia Chen; Chi Pui Pang
Journal:  Ophthalmology       Date:  2018-07-06       Impact factor: 12.079

2.  Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes.

Authors:  Jacinto Santodomingo-Rubido; César Villa-Collar; Bernard Gilmartin; Ramón Gutiérrez-Ortega
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-31       Impact factor: 4.799

3.  Decrease in rate of myopia progression with a contact lens designed to reduce relative peripheral hyperopia: one-year results.

Authors:  Padmaja Sankaridurg; Brien Holden; Earl Smith; Thomas Naduvilath; Xiang Chen; Percy Lazon de la Jara; Aldo Martinez; Judy Kwan; Arthur Ho; Kevin Frick; Jian Ge
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-09       Impact factor: 4.799

4.  Atropine for the treatment of childhood myopia.

Authors:  Wei-Han Chua; Vivian Balakrishnan; Yiong-Huak Chan; Louis Tong; Yvonne Ling; Boon-Long Quah; Donald Tan
Journal:  Ophthalmology       Date:  2006-09-25       Impact factor: 12.079

Review 5.  Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050.

Authors:  Brien A Holden; Timothy R Fricke; David A Wilson; Monica Jong; Kovin S Naidoo; Padmaja Sankaridurg; Tien Y Wong; Thomas J Naduvilath; Serge Resnikoff
Journal:  Ophthalmology       Date:  2016-02-11       Impact factor: 12.079

6.  Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).

Authors:  Audrey Chia; Wei-Han Chua; Yin-Bun Cheung; Wan-Ling Wong; Anushia Lingham; Allan Fong; Donald Tan
Journal:  Ophthalmology       Date:  2011-10-02       Impact factor: 12.079

7.  Prevalence and progression of myopic retinopathy in an older population.

Authors:  Jerry Vongphanit; Paul Mitchell; Jie Jin Wang
Journal:  Ophthalmology       Date:  2002-04       Impact factor: 12.079

8.  Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial.

Authors:  Pauline Cho; Sin-Wan Cheung
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-10-11       Impact factor: 4.799

Review 9.  Controlling myopia progression in children and adolescents.

Authors:  Molly J Smith; Jeffrey J Walline
Journal:  Adolesc Health Med Ther       Date:  2015-08-13

10.  Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial.

Authors:  Carly Siu Yin Lam; Wing Chun Tang; Dennis Yan-Yin Tse; Roger Pak Kin Lee; Rachel Ka Man Chun; Keigo Hasegawa; Hua Qi; Takashi Hatanaka; Chi Ho To
Journal:  Br J Ophthalmol       Date:  2019-05-29       Impact factor: 4.638

View more
  15 in total

1.  Treatment zone decentration promotes retinal reshaping in Chinese myopic children wearing orthokeratology lenses.

Authors:  Xue Li; Yingying Huang; Jiali Zhang; Chenglu Ding; Yunyun Chen; Hao Chen; Jinhua Bao
Journal:  Ophthalmic Physiol Opt       Date:  2022-05-22       Impact factor: 3.992

2.  Myopia Control With Multifocal Lens in School-Aged Children: A Meta-Analysis.

Authors:  Meilan Chen; Lu Xu; Hongyang Li; Fengping Cai; Hao Wang; Chun Hu; Yi Wu
Journal:  Front Pediatr       Date:  2022-06-20       Impact factor: 3.569

3.  Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response.

Authors:  Henry H L Chan; Kai Yip Choi; Alex L K Ng; Bonnie N K Choy; Jonathan Cheuk Hung Chan; Sonia S H Chan; Serena Z C Li; Wing Yan Yu
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

Review 4.  Myopia: Mechanisms and Strategies to Slow Down Its Progression.

Authors:  Andrea Russo; Alessandro Boldini; Davide Romano; Giuseppina Mazza; Stefano Bignotti; Francesco Morescalchi; Francesco Semeraro
Journal:  J Ophthalmol       Date:  2022-06-14       Impact factor: 1.974

5.  Reduction of Myopic Progression Using a Multifocal Soft Contact Lens: A Retrospective Cohort Study.

Authors:  Jeffrey Cooper; Brett O'Connor; Thomas Aller; Sally M Dillehay; Katherine Weibel; Douglas Benoit
Journal:  Clin Ophthalmol       Date:  2022-07-04

6.  Photorefraction Screening Plus Atropine Treatment for Myopia is Cost-Effective: A Proof-of-Concept Markov Analysis.

Authors:  Chuen Yen Hong; Matt Boyd; Graham Wilson; Sheng Chiong Hong
Journal:  Clin Ophthalmol       Date:  2022-06-13

7.  Effect of Combining 0.01% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children.

Authors:  Jenny Huang Jones; Donald O Mutti; Lisa A Jones-Jordan; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2022-02-25       Impact factor: 2.106

8.  A Clinical Study of the Impact of Soft Contact Lenses on the Progression of Myopia in Young Patients.

Authors:  Andrzej Malinowski; Małgorzata Mrugacz; Marcin Stopa; Erita Filipek; Anna Moniuszko-Malinowska; Piotr Czupryna
Journal:  Clin Ophthalmol       Date:  2022-01-11

9.  Comparison between estimated and measured myopia progression in Hong Kong children without myopia control intervention.

Authors:  Yajing Yang; Sin Wan Cheung; Pauline Cho; Stephen J Vincent
Journal:  Ophthalmic Physiol Opt       Date:  2021-10-01       Impact factor: 3.992

Review 10.  [Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses].

Authors:  Hakan Kaymak; Birte Graff; Kai Neller; Achim Langenbucher; Berthold Seitz; Hartmut Schwahn
Journal:  Ophthalmologe       Date:  2021-07-08       Impact factor: 1.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.